FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
Executive Summary
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.
You may also be interested in...
US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.
US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.
Par Fights FDA Forfeiture Of Generic Colcrys Exclusivity
Pursing legal action against the agency in an area where it is sometimes vulnerable, Par argues that amending its proposed label did not interrupt paragraph IV certification for the firm's colchicine ANDA.